PL3849583T3 - Peptydy do leczenia neowaskularnych chorób oczu - Google Patents

Peptydy do leczenia neowaskularnych chorób oczu

Info

Publication number
PL3849583T3
PL3849583T3 PL19784137.2T PL19784137T PL3849583T3 PL 3849583 T3 PL3849583 T3 PL 3849583T3 PL 19784137 T PL19784137 T PL 19784137T PL 3849583 T3 PL3849583 T3 PL 3849583T3
Authority
PL
Poland
Prior art keywords
peptides
eye diseases
treating neovascular
neovascular eye
treating
Prior art date
Application number
PL19784137.2T
Other languages
English (en)
Inventor
Menotti Ruvo
Davide ROSIELLO
Sandro De Falco
Original Assignee
Anbition S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anbition S.R.L. filed Critical Anbition S.R.L.
Publication of PL3849583T3 publication Critical patent/PL3849583T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL19784137.2T 2018-09-11 2019-09-11 Peptydy do leczenia neowaskularnych chorób oczu PL3849583T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT201800008507 2018-09-11
PCT/IB2019/057637 WO2020053773A1 (en) 2018-09-11 2019-09-11 Peptides and medical uses thereof

Publications (1)

Publication Number Publication Date
PL3849583T3 true PL3849583T3 (pl) 2026-05-04

Family

ID=64556987

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19784137.2T PL3849583T3 (pl) 2018-09-11 2019-09-11 Peptydy do leczenia neowaskularnych chorób oczu

Country Status (10)

Country Link
US (1) US12653859B2 (pl)
EP (1) EP3849583B1 (pl)
JP (1) JP2022500463A (pl)
KR (1) KR102984392B1 (pl)
CN (1) CN113015539B (pl)
AU (1) AU2019340465B2 (pl)
CA (1) CA3112175A1 (pl)
ES (1) ES3059284T3 (pl)
PL (1) PL3849583T3 (pl)
WO (1) WO2020053773A1 (pl)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
DK1297016T3 (da) * 2000-05-12 2006-07-10 Vlaams Interuniv Inst Biotech Anvendelse af placentavækstfaktorinhibitorer til behandling af patologisk angiogenese, patologisk arteriogenese, inflammation, tumordannelse og/eller vaskulær lækage
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20060088882A1 (en) * 2002-06-27 2006-04-27 Jain Rakesh K Methods for the treatment or prevention of obesity
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
MX2013011366A (es) * 2011-03-30 2014-05-12 Chugai Pharmaceutical Co Ltd Retencion de las moleculas de union al antigeno en el plasma sanguineo y metodo para modificar la inmunogenicidad.
JP6184404B2 (ja) * 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
KR102359396B1 (ko) * 2013-11-22 2022-02-08 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
RU2708375C2 (ru) * 2015-03-02 2019-12-06 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс Пептиды для ингибирования ангиогенеза
KR20210062649A (ko) * 2018-09-11 2021-05-31 앤비션 에스.알.엘. 펩티드 및 이의 의학적 용도

Also Published As

Publication number Publication date
KR20210062650A (ko) 2021-05-31
EP3849583B1 (en) 2025-12-31
KR102984392B1 (ko) 2026-06-29
EP3849583A1 (en) 2021-07-21
ES3059284T3 (en) 2026-03-19
CN113015539B (zh) 2025-01-07
US20220054583A1 (en) 2022-02-24
CA3112175A1 (en) 2020-03-19
JP2022500463A (ja) 2022-01-04
EP3849583C0 (en) 2025-12-31
CN113015539A (zh) 2021-06-22
US12653859B2 (en) 2026-06-16
WO2020053773A1 (en) 2020-03-19
AU2019340465A1 (en) 2021-05-13
AU2019340465B2 (en) 2025-08-14

Similar Documents

Publication Publication Date Title
IL277333A (en) Methods for treating eye diseases
SG11202104461XA (en) Therapeutic methods
GB201820166D0 (en) Therapeutic agents
IL277190A (en) Methods of treating HPV-related diseases
GB201909190D0 (en) Therapeutic agents
GB201820165D0 (en) Therapeutic agents
IL281449A (en) Anti-ifnar1 antibodies for the treatment of autoimmune diseases
GB201909191D0 (en) Therapeutic agents
PL4122464T3 (pl) Kombinacje terapeutyczne do leczenia chorób wątroby
GB201909194D0 (en) Therapeutic agents
GB201902277D0 (en) Therapeutic agents
DK3737402T3 (en) Modificeret protein
IL290520A (en) Medicinal peptides
SG11202104178TA (en) Peptides and pharmaceutical compositions for treating eye diseases
IL273929A (en) Therapeutic agents for neurodegenerative diseases
GB201805816D0 (en) Therapeutic agents
IL285144A (en) Medicinal peptides
IL265708A (en) Therapeutic protein
SG11202102827YA (en) Treatment methods
GB201906804D0 (en) Therapeutic agents
SG11202005278PA (en) Compounds for treating eye diseases and methods thereof
GB201805554D0 (en) Therapy for protein misfolding disease
IL268046A (en) Therapeutic peptides
GB201820162D0 (en) Therapeutic agents
GB201820160D0 (en) Therapeutic agents